🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Sheri L. Holmen

University of Utah

ORCID: 0000-0002-6411-6032

Also affiliated with Huntsman Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.386Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

PLoS ONE(2023)10.1371/journal.pone.0269324
Top 47%
0.386DataRank
Top 47%10 citations

Keimya Sadeghi, Sharon N. Edmiston, Jessica M. Kenney, Cecilia Lezcano, James S. Wilmott +47 more

Papers

Driven by 22 papers — median percentile 26. Top paper: “Melanoma models for the next generation of therapies”.

Melanoma models for the next generation of therapies

Cancer Cell(2021)10.1016/j.ccell.2021.01.011
N/A
0.816DataRank · unranked
230 citations

Kristen L. Mueller, David J. Adams, Niroshana Anandasabapathy, Andrew E. Aplin, Corine Bertolotto +31 more

Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines

Cancer Research(2020)10.1158/0008-5472.can-20-0291
N/A
0.729DataRank · unranked
128 citations

Amanda E.D. Van Swearingen, Carey K. Anders, Amos Bairoch, Adrienne Boire, Paula D. Bos +21 more

Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study

Pigment Cell & Melanoma Research(2022)10.1111/pcmr.13058
N/A
0.672DataRank · unranked
21 citations

Ronglai Shen, Arshi Arora, Irene Orlow, Klaus J. Busam, Cecilia Lezcano +40 more

Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy

Nature Communications(2024)10.1038/s41467-024-50881-1
N/A
0.478DataRank · unranked
8 citations

Junhua Wang, Emily Wilson, Coulson P. Rich, Aaron Rogers, Zongzhong Tong +14 more

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

Pigment Cell & Melanoma Research(2022)10.1111/pcmr.13059
N/A
0.425DataRank · unranked
16 citations

Maya Dimitrova, Kevin Kleffman, Christopher Alvarez‐Breckenridge, Michael B. Atkins, Adrienne Boire +22 more

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

PLoS ONE(2023)10.1371/journal.pone.0269324
Top 47%
0.386DataRank
Top 47%10 citations

Keimya Sadeghi, Sharon N. Edmiston, Jessica M. Kenney, Cecilia Lezcano, James S. Wilmott +47 more

DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance

JCO Precision Oncology(2024)10.1200/po-24-00375
N/A
0.327DataRank · unranked
6 citations

Sharon N. Edmiston, Amanda M. Vondras, Allison Reiner, David L. Corcoran, Ronglai Shen +70 more

Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study

UNC Libraries(2023)10.17615/43x8-9d17
N/A
0.165DataRank · unranked
2 citations

M. Berwick, InterMEL, Li Luo, Judy R. Rees, Sheri L. Holmen +40 more

The carnosinase dipeptidase CNDP1 is a novel metabolic vulnerability in brain metastasis

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.03.18.644053
N/A
0.104DataRank · unranked
1 citations

Alcida Karz, Maya Navarro, Victoria Osorio-Vasquez, Olga Katsara, Adam K. Walker +21 more

Untitled

Journal of Cancer Immunology(2024)10.33696/cancerimmunol.6.3
N/A
0DataRank · unranked
0 citations

Sheri L. Holmen, Gennie L. Parkman

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Cancer Cell(2025)10.1016/j.ccell.2025.02.001
N/A
0DataRank · unranked
38 citations

Rodolfo Daniel Cervantes‐Villagrana, Farhoud Faraji, Sydney I. Ramirez, Kuniaki Sato, Sendi Rafael Adame-Garcia +15 more

Targeting FAK to Potentiate Immune Checkpoint Therapy in Solid Tumors

Journal of Cancer Immunology(2025)10.33696/cancerimmunol.7.109
N/A
0DataRank · unranked
7 citations

Sheri L. Holmen, Karly A. Stanley

Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.101943
N/A
0DataRank · unranked
12 citations

Tursun Turapov, David A. Kircher, Karly A. Stanley, Katie M. Culver, A. Paulina Medellin +7 more

Protocol for developing a melanoma brain metastasis mouse model for preclinical drug testing and brain tumor progression monitoring

STAR Protocols(2025)10.1016/j.xpro.2025.104081
N/A
0DataRank · unranked
0 citations

Tursun Turapov, Sheri L. Holmen, Jared Almazan

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma

UNC Libraries(2020)10.17615/73y8-rn80
N/A
0DataRank · unranked
7 citations

Gatien Moriceau, Robert Damoiseaux, Roger S. Lo, Lu Sun, Aayoung Hong +5 more

BRAF V600E induces reversible mitotic arrest in human melanocytes via microRNA-mediated suppression of AURKB

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.21.109397
N/A
0DataRank · unranked
0 citations

R.L. Belote, Hanlin Zeng, Marcus Urquijo, Kendra Barker, Rodrigo Torres +12 more

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma

Cancer Reports(2021)10.1002/cnr2.1419
N/A
0DataRank · unranked
10 citations

Benjamin Haaland, Siwen Hu‐Lieskovan, Howard Colman, Sheri L. Holmen, Xuechen Wang

Genetic silencing of AKT induces melanoma cell death

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.08.15.504039
N/A
0DataRank · unranked
2 citations

Tursun Turapov, David A. Kircher, William J. Burnett, Christopher M. Stehn, Kayla O’Toole +11 more

Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0474
N/A
0DataRank · unranked
8 citations

Tursun Turapov, David A. Kircher, William J. Burnett, Christopher M. Stehn, Kayla O’Toole +13 more

Data from Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma

(2023)10.1158/0008-5472.c.6499695.v1
N/A
0DataRank · unranked
0 citations

Monique Verhaegen, Marı́a S. Soengas, Sheri L. Holmen, Matthew W. VanBrocklin

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

UNC Libraries(2023)10.17615/btmj-c685
Top 100%
0DataRank
Top 100%0 citations

R.A. Scolyer, C.B. Begg, Iman Osman, C Timothy Thompson, Elise K. Brunsgaard +48 more

A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies

Journal of Cancer Immunology(2024)10.33696/cancerimmunol.6.089
N/A
0DataRank · unranked
8 citations

Sheri L. Holmen, Gennie L. Parkman